Neoplasms

Symptoms and General Pathology

All Conditions

Immune System Diseases

Nervous System Diseases

Neoplasm Metastasis

Hypersensitivity

Body Weight

Brain Neoplasms

Neoplastic Processes

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Patients with brain metastases who will receive radiotherapy to the brain will undergo diffusion-weighted magnetic resonance imaging (MRI) at the same time as dose planning MRI is performed, after end of radiotherapy, and after 3 and 6 months after end of radiotherapy.

Brain metastases radiation according to clinical practice.

Brain metastases radiation

Sara Alkner, MD, PhD

Minn Lerner, Radiation physicist

Minna Lerner, Radiation physict

Stereotactic radiation therapy is an important and common method of treating brain metastases in patients with malignant disease. Today, however, there are no methods available to determine the metastasis' radiation sensitivity in advance and treatment responses can only be seen by changing of the size of the metastasis on conventional X-ray examinations, computed tomography (CT) and magnetic resonance imaging (MRI). Changes in the size of the metastases is something that is often seen weeks / months after treatment is completed. At Lund University Hospital, a new imaging technique, diffusional variance decomposition (DIVIDE), has now been developed. With this technique, the scatter in isotropic and anisotropic diffusion can be measured for each measuring point, which provides significantly more information about the properties of the tissue compared to current methods.

Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of Central Nervous System (CNS) Metastases

Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of CNS Metastases

Evaluation done by MRI to see whether radiation sensitivity can be measured during radiotherapy and after 3 and 6 months after end of treatment.

Evaluation done by MRI to see whether early changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.

Evaluation done by MRI to see whether changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.

Evaluation done by MRI to see whether differentiation between radionecrosis and residual/recurrent tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.

Evaluation done by MRI to see whether differentiation between radionecrosis and residual/recurrent tumor can be measured during radiotherapy after 3 months after end of treatment.

Evaluation done by MRI to see whether differentiation between radionecrosis and residual/recurrent tumor can be measured during radiotherapy and after and 6 months after end of treatment.

Lund University Hospital

Behaviors and Mental Disorders

Head and Neck Neoplasms

Quality of Life

Patients with adjuvant or definitve radiotherapy or radio-chemotherapy for head and neck cancer

3x3 OCT volume scans on treated and opposite side of the irreadiated area on head and neck

Dermatoscope

Blood sample is examined for breaks per metaphase to determine radiation sensibility of the individual

3-Colour FISH

Elisabeth Silberberger, MSc

Hans Geinitz, Prim. Univ.-Prof. Dr.

Elisabeth Silberberger, MSC

The purpose of this study is to determine whether any eventual skin damage caused by radiation therapy can be detected and monitored at a subclinical level via optical coherence tomography (OCT). Another key question is whether subclinical OCT detected skin damage correlates with acute and late clinical toxicity.

Head and neck cancer patients that meet the eligibility criteria and singned the informed consent will undergo OCT-measurements before, during and after the course of radiation therapy. At the same time-points the skin areas are evaluated with dermatoscopy and patients are asked to self-assess their quality of life (EORTC QLQ C30 and respective head and neck module H\&N 43). Before the onset of radiation therapy radiation sensitivity analysis will be performed with in-vitro irradion of peripheral blood lymphocytes (FISH).

Optical Coherence Tomography in Patients With Radiotherapy for Head and Neck Cancer

Live Laser Microscopic Evaluation (OCT) of Radiation Induced Preclinical Alterations of the Skin in Head and Neck Cancer Patients

any reproducible difference in skin OCT appearance as compared with baseline (pre-RT)

Correlation of OCT changes with CTC radiation toxicity

Correlation of OCT with chromosome-breaks per metaphasis in in-vitro irradiated blood lymphocytes (FISH)

Correlation of OCT changes with standardised evaluated skin appearence via dermatoscopy

Correlation of quality of live as measured with the EORT QLC C30 and Head and neck module H\&N 43 with OCT and radiation sensitivity

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of Central Nervous System (CNS) Metastases	NCT04700748	Radiotherapy Brain Metastase... Sensitivity Radionecrosis	Brain metastase...	18 Years -	Lund University Hospital
Optical Coherence Tomography in Patients With Radiotherapy for Head and Neck Cancer	NCT04610645	Head and Neck C... Radiotherapy	OCT Dermatoscope 3-Colour FISH	18 Years - 99 Years	Krankenhaus Barmherzige Schwestern Linz

Spots Global Cancer Trial Database for radiation sensitivity